StreetInsider.com News Articles

Form 4 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert

Tue, 23 Jun 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260623/26680830.html

Form 4 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert

Tue, 23 Jun 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260623/26680830.html

Form 3 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert

Tue, 23 Jun 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260623/26680818.html

Form 3 Tango Therapeutics, Inc. For: Jun 19 Filed by: Azelby Robert

Tue, 23 Jun 2026 18:04:00 -0400

si-local-file:///var/storage/secattach/20260623/26680818.html

Form 8-K Tango Therapeutics, Inc. For: Jun 19

Tue, 23 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260623/26680578.html

Form 8-K Tango Therapeutics, Inc. For: Jun 19

Tue, 23 Jun 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260623/26680578.html

Tango Therapeutics adds Robert Azelby to its board of directors

Mon, 22 Jun 2026 16:05:31 -0400

Tango Therapeutics, Inc. (NASDAQ: TNGX) announced the appointment of Robert Azelby to its board of directors, according to a company press release.

Azelby brings more than 30 years of experience in the biopharmaceutical industry, including roles in oncology commercialization and corporate strategy. He previously served as president and chief executive officer of Eliem Therapeutics from October 2020 to February 2023, and as CEO of Alder BioPharmaceuticals from June 2018 until its acquisition by H. Lundbeck in 2019. He also served as executive vice president and chief commercial officer of Juno Therapeutics until its acquisition by Celgene in 2018.

Earlier in his career,

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Mon, 22 Jun 2026 16:05:00 -0400

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. His appointment comes as Tango advances vopimetostat, its investigational PRMT5 inhibitor with first- and best-in-class potential, toward potential late-stage development for patients with pancreatic cancer.

“As Tango continues to evolve

Tango Therapeutics Appoints Robert Azelby to Board of Directors

Mon, 22 Jun 2026 16:05:00 -0400

“As Tango continues to evolve

Form 144 Tango Therapeutics, Inc. Filed by: NEXTECH CROSSOVER I SCSP

Wed, 17 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260617/26660657.html

Form 144 Tango Therapeutics, Inc. Filed by: NEXTECH CROSSOVER I SCSP

Wed, 17 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260617/26660657.html

Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella

Thu, 11 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260611/26637009.html

Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella

Thu, 11 Jun 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260611/26637009.html

Form 8-K Tango Therapeutics, Inc. For: Jun 09

Wed, 10 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260610/26630934.html

Form 8-K Tango Therapeutics, Inc. For: Jun 09

Wed, 10 Jun 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260610/26630934.html

Form 424B5 Tango Therapeutics, Inc.

Wed, 10 Jun 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260610/26630921.html

Form 424B5 Tango Therapeutics, Inc.

Wed, 10 Jun 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260610/26630921.html

Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella

Wed, 10 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260610/26630570.html

Form 144 Tango Therapeutics, Inc. Filed by: Beckman Daniella

Wed, 10 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260610/26630570.html

Tango Therapeutics Inc. (TNGX) PT Raised to $66 at H.C. Wainwright

Wed, 10 Jun 2026 07:12:22 -0400

(Updated - June 10, 2026 7:12 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $66.00 (from $27.00) while maintaining a Buy rating.

The analyst commented: "Yesterday, Tango announced initial Phase 1 results for the combination of vopimetostat + daraxonrasib in 2L+ PDAC (n=20; 65% 2 median prior Rx; 70% liver mets) and NSCLC (n=5; 60% 2 median prior Rx; 20% liver mets). As seen in the company presentation, vopimetostat 200mg or 250mg + daraxonrasib 100mg demonstrated a 92% ORR and 100% ORR in the PDAC and NSCLC patients, respectively, and a 90%

Tango Therapeutics Inc. (TNGX) PT Raised to $66 at H.C. Wainwright

Wed, 10 Jun 2026 07:12:22 -0400

(Updated - June 10, 2026 7:12 AM EDT)

H.C. Wainwright analyst Robert Burns raised the price target on Tango Therapeutics Inc. (NASDAQ: TNGX) to $66.00 (from $27.00) while maintaining a Buy rating.

Form FWP Tango Therapeutics, Inc. Filed by: Tango Therapeutics, Inc.

Wed, 10 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260610/26626093.html

Form FWP Tango Therapeutics, Inc. Filed by: Tango Therapeutics, Inc.

Wed, 10 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260610/26626093.html

Tango Therapeutics prices $600 million public offering at $30 per share

Tue, 09 Jun 2026 22:49:37 -0400

Tango Therapeutics Inc. (NASDAQ: TNGX) announced the pricing of an underwritten public offering of 18,166,667 shares of common stock and pre-funded warrants to purchase up to 1,833,395 shares at $30.00 per share. The pre-funded warrants are priced at $29.999 each, representing the share price minus the $0.001 exercise price.

The clinical-stage biotechnology company expects gross proceeds of approximately $600 million before underwriting discounts and offering expenses. The offering is scheduled to close on or around June 11, 2026, subject to standard closing conditions.

Tango has granted underwriters a 30-day option to purchase up to an additional 3,000,009 shares at the public offering

Tango Therapeutics prices $600 million public offering at $30 per share

Tue, 09 Jun 2026 22:49:37 -0400

Tango has granted underwriters a 30-day option to purchase up to an additional 3,000,009 shares at the public offering